In a report published on Monday, Leerink analyst Joseph Schwartz noted that BioMarin's BMRN announcement of its full Phase 1/2 data on poly ADP-ribose polymerase (PARP) inhibitor BMN 673 for the treatment of solid tumors showed good responses in BRCA cancer and breast cancer patients. Schwartz reiterated BioMarin with an Outperform rating and a price target of $70.00.
In the announcement, BioMarin said that drug response rates in patient exceeded 30% threshold, this might be an underestimate because many patients haven't received the maximum tolerated dose.
According to Bloomberg data, BioMarin has 17 buy ratings and 7 holds. Prior to today, shares of the its stock gained 27 percent YTD. Shares are down about 7.6 percent today.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in